Robotics is designed so that people can do what they can't
It all began with a question that a young engineer couldn't get out of his head. In a robotics club at the École polytechnique, Nicolas Simon watched a machine learn to walk and thought of his brother, who was losing that ability. If a robot can walk, why can't we build one that walks for him?
Wandercraft was founded in Paris in 2012 to address this challenge, and the solution took a decade of engineering: a self-balancing exoskeleton, so the person inside doesn't have to. In 2019, Atalante became the first self-balancing walking exoskeleton to earn a CE mark in Europe.
That same technology now supports people through rehabilitation at more than 150 clinical and research sites, is moving out of the clinic and into the home with Eve, and powers Calvin, our family of humanoid robots built for the toughest industrial tasks. Three products, two markets, one conviction—robotics should help people do what they can’t.
The same self-balancing technology across three scales—from a clinical exoskeleton to a humanoid designed for the factory floor.
Our clinical exoskeleton enables patients to walk hands-free during rehabilitation, without crutches.
Our personal exoskeleton, designed to leave the clinic and go home with the person wearing it.
Our humanoid robot, designed for the heaviest and most repetitive tasks on an industrial floor.
Fourteen years, three robots, and one idea that just wouldn't go away. Swipe sideways to follow it.
Nicolas Simon, Matthieu Masselin, and Jean-Louis Constanza founded Wandercraft in Paris—inspired by a brother and a son who were losing the ability to walk.
The world's first clinical trials using our prototypes show that people with paraplegia can walk hands-free, without crutches.
The world's first self-balancing exoskeleton has been approved in Europe, and patients are now using it to walk in rehabilitation clinics.
Atalante has been cleared by the FDA for stroke rehabilitation, paving the way for use in American clinics—and for operations in the U.S. the following year.
At Paris 2024, our exoskeletons carry the Olympic and Paralympic torches—including Thibault Simon, the brother whose story started it all.
Our self-balancing personal exoskeleton is entering clinical trials with people living with spinal cord injuries at the Bronx VA and Kessler.
Renault Group is taking a stake in the company and joining us as an industrial partner, as part of a Series D funding round aimed at scaling up production worldwide.
Built on more than a decade of exoskeleton engineering, the first Calvin prototype takes shape in 40 days. Calvin-40 is unveiled, with the Renault Group as its first customer.
Calvin-40 is in operation on the production line at Renault's Douai plant, with a fleet of 350 robots scheduled to be deployed by 2027.
Eve becomes the first self-balancing personal exoskeleton approved for home use by people with spinal cord injuries.
More than 175 world-class experts in AI, robotics, and industry, working from our dual headquarters in Paris and New York.
We're not just hiring people. We're building a team of pioneers, curious minds, and problem solvers who want to change the world, one step at a time.
Apply
Our Paris office has its own walking center; there’s another one in New York City, and more are opening across the U.S. Users work out in the building every day, so no one here has to wonder who the facility is for.
Whole-body control, embedded AI, certifiable safety, robots that carry people and robots that carry payloads—and a production line waiting for the answer.
Our in-house Expert Track allows engineers to delve deeper into a specialty rather than working their way up the ranks. Seniority here is not just a headcount.
Paris and New York, brought together on purpose: company-wide events every year, and commitments to employee well-being that we actually put in writing.
Come help shape the next generation of medical and humanoid robotics, powered by AI and a clear purpose.
